
InDex Pharmaceuticals Q3 2023 - Uncertain future post discontinuation of CONCLUDE

Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE. The share trades at a substantial discount compared to its book value, which offers an interesting play on the company's future trajectory.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[InDex Pharmaceuticals Q3 2023 - Uncertain future post discontinuation of CONCLUDE](#)